secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-020608
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q4 net income $142.8M; cash $1.2B, runway to 2027
-------------------------------------------------------------------

- Q4 net income $142.8M ($1.77 basic EPS) vs net loss $38.3M in Q4 2022; full-year net loss $132.5M vs $289.1M loss in 2022.
- Cash, equivalents and marketable securities $1.2B at Dec 31, 2023, expected to fund operations into 2027.
- BEAM-101 in SCD: sentinel cohort dosing and expansion cohort initiation H1 2024; initial clinical data expected H2 2024.
- BEAM-302 for AATD Phase 1 trial initiation on track for H1 2024 pending CTA acceptance; BEAM-301 IND submission H1 2024.
- R&D expenses rose to $140.1M Q4 (vs $86.3M) and $437.4M FY (vs $311.6M); G&A expenses $43.3M Q4 (vs $22.7M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/beam-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer